Special Issue

Advances in Translational Oncology and Oncometabolism

Message from the Guest Editors

Recent advances in oncometabolism have deepened our understanding of the metabolic alterations in cancer cells, highlighting the potential for metabolic-based diagnostics and therapies in oncology. Tumour metabolism has been identified a newer hallmark of cancer that supports their rapid growth and survival. Many oncogenes and tumour suppressor genes regulate metabolism as part of their mechanism in driving tumorigenesis. Recent technological advancements in oncometabolism include highthroughput techniques to enable the comprehensive analysis of metabolic profiles and identify metabolic alterations in cancer cells. Cancer cells often undergo significant metabolic changes to meet the bioenergetic and biosynthetic demands of rapid proliferation. Cancer stem cells are often linked to altered tumour metabolism and failure to respond to various cancer treatments. Identifying specific oncometabolites can lead to development of diagnostic biomarkers for early cancer detection. Furthermore, understanding how the tumour microenvironment influences metabolism in the context of molecular mutations could pave the way for more effective, personalized therapies across various types of cancer.

Guest Editors

Dr. Graham Pidgeon


Department of Surgery, Trinity Translational Medicine Institute, Trinity College Dublin, St. James's Hospital, Dublin 8, Ireland

Dr. Zivile Useckaite

Department of Anatomical Pathology, Flinders Medical Centre, College of Medicine and Public Health, Flinders University, Adelaide, SA 5042, Australia

Deadline for manuscript submissions

30 June 2026



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/232133

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

